OBJECTIVES: Oral treatment (targeted or chemotherapy) for cancer is being increasingly used. While fatigue is a known side effect of intravenous chemotherapy, the rate of fatigue and the impact of fatigue on other patient-reported outcomes are not well described. METHOD: At Massachusetts General Hospital Cancer Center, 180 adult patients prescribed oral targeted or chemotherapy for various malignancies enrolled in a randomized controlled trial of adherence and symptom management. Patients completed baseline self-reported measures of fatigue (Brief Fatigue Inventory; BFI), anxiety and depressive symptoms (Hospital Anxiety and Depression Scale; HADS), and quality of life, including subscales for physical, social, emotional, and functional well-being ([QOL] Functional Assessment of Cancer Therapy - General; FACT-G). We examined clinically relevant fatigue using a validated cut-off score for moderate-severe fatigue (BFI global fatigue ≥4) and tested the associations with anxiety symptoms, depressive symptoms, and QOL with independent samples t-tests. RESULTS: At baseline, 45 of 180 participants (25.0%) reported moderate-severe fatigue. Fatigued patients experienced more anxiety symptoms (mean diff. 3.73, P < 0.001), more depressive symptoms (mean diff. 4.14, P < 0.001), and worse QOL on the total FACT-G score (mean diff. -19.58, P < 0.001) and all subscales of the FACT-G compared to patients without moderate-severe fatigue. SIGNIFICANCE OF RESULTS: One in four patients on oral treatment for cancer experienced clinically relevant fatigue that is associated with greater anxiety and depressive symptoms and worse QOL.
OBJECTIVES: Oral treatment (targeted or chemotherapy) for cancer is being increasingly used. While fatigue is a known side effect of intravenous chemotherapy, the rate of fatigue and the impact of fatigue on other patient-reported outcomes are not well described. METHOD: At Massachusetts General Hospital Cancer Center, 180 adult patients prescribed oral targeted or chemotherapy for various malignancies enrolled in a randomized controlled trial of adherence and symptom management. Patients completed baseline self-reported measures of fatigue (Brief Fatigue Inventory; BFI), anxiety and depressive symptoms (Hospital Anxiety and Depression Scale; HADS), and quality of life, including subscales for physical, social, emotional, and functional well-being ([QOL] Functional Assessment of Cancer Therapy - General; FACT-G). We examined clinically relevant fatigue using a validated cut-off score for moderate-severe fatigue (BFI global fatigue ≥4) and tested the associations with anxiety symptoms, depressive symptoms, and QOL with independent samples t-tests. RESULTS: At baseline, 45 of 180 participants (25.0%) reported moderate-severe fatigue. Fatigued patients experienced more anxiety symptoms (mean diff. 3.73, P < 0.001), more depressive symptoms (mean diff. 4.14, P < 0.001), and worse QOL on the total FACT-G score (mean diff. -19.58, P < 0.001) and all subscales of the FACT-G compared to patients without moderate-severe fatigue. SIGNIFICANCE OF RESULTS: One in four patients on oral treatment for cancer experienced clinically relevant fatigue that is associated with greater anxiety and depressive symptoms and worse QOL.
Entities:
Keywords:
Cancer; Fatigue; Oral chemotherapy; Quality of life; Targeted therapy
Authors: Alla Sikorskii; Charles W Given; Barbara A Given; Eric Vachon; John C Krauss; Margaret Rosenzweig; Ruth McCorkle; Victoria L Champion; Asish Banik; Atreyee Majumder Journal: J Pain Symptom Manage Date: 2018-08-08 Impact factor: 3.612
Authors: Hanneke Poort; Winette T A van der Graaf; Ronald Tielen; Myrella Vlenterie; José A E Custers; Judith B Prins; Constans A H H V M Verhagen; Marieke F M Gielissen; Hans Knoop Journal: J Pain Symptom Manage Date: 2016-05-24 Impact factor: 3.612
Authors: Zeeshan Butt; Sarah K Rosenbloom; Amy P Abernethy; Jennifer L Beaumont; Diane Paul; Debra Hampton; Paul B Jacobsen; Karen L Syrjala; Jamie H Von Roenn; David Cella Journal: J Natl Compr Canc Netw Date: 2008-05 Impact factor: 11.908
Authors: R Lobefaro; S Rota; L Porcu; C Brunelli; S Alfieri; E Zito; I Taglialatela; M Ambrosini; A Spagnoletti; M Zimatore; G Fatuzzo; F Lavecchia; C Borreani; G Apolone; F De Braud; M Platania Journal: ESMO Open Date: 2022-03-31
Authors: Xuan Qiu; Manjiang Li; Liqun Wu; Yang Xin; Siyu Mu; Tianxiang Li; Kangjian Song Journal: Cancer Manag Res Date: 2020-09-04 Impact factor: 3.989
Authors: Evie E M Kolsteren; Esther Deuning-Smit; Alanna K Chu; Yvonne C W van der Hoeven; Judith B Prins; Winette T A van der Graaf; Carla M L van Herpen; Inge M van Oort; Sophie Lebel; Belinda Thewes; Linda Kwakkenbos; José A E Custers Journal: Cancers (Basel) Date: 2022-08-11 Impact factor: 6.575